Article
Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study.
Cardiovascular drugs and therapy - 1 Aug 2020
Langslet Gisle, Hovingh G Kees, Guyton John R, Baccara-Dinet Marie T, Letierce Alexia, Manvelian Garen, Farnier Michel
Abstract excerpt
PURPOSE: During the alirocumab open-label extension study ODYSSEY OLE (open-label extension; NCT01954394), physicians could adjust alirocumab dosing for enrolled patients, who were diagnosed with heterozygous familial hypercholesterolemia (HeFH) and who had completed previous phase III clinical trials with alirocumab. This post hoc analysis evaluated the differences in physician-patient dosing decisions between...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.